Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dissapointed

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 28, 2021 6:56pm

178 Views

Post# 32682676

RE:RE:Dissapointed

cashcrab wrote: if the dillution was 22% and the money went into the companies bank accoun,t the value of the company is the same no? just re arreanged

Well said cashcrab.

I'd also like to add that without cash we are desperate and vulnerable.
Now ... we're independant - getting that nose job, pec implant and maybe even a new pair of calves.

Look out Arnold - we're gunning for ya !

: )

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing